Recursion Pharmaceuticals, Inc.
RXRX
$6.35
$0.416.90%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -92.38% | -3.04% | -27.13% | -39.87% | -61.75% |
| Total Depreciation and Amortization | 71.47% | -5.01% | 61.79% | 97.88% | 135.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.49% | 57.55% | 20.09% | 43.04% | 123.43% |
| Change in Net Operating Assets | 153.66% | 159.75% | -1.41% | -49.36% | -1,775.21% |
| Cash from Operations | -55.82% | 18.78% | -21.87% | -39.53% | -65.54% |
| Capital Expenditure | 37.20% | -512.35% | 70.21% | -28.56% | 74.09% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 390,387.32% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00% | -100.00% | -- | -- | -- |
| Cash from Investing | 11,171.38% | -1,214.70% | -103.70% | -24.59% | 68.82% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -202.74% | -9,429.17% | -8.33% | -8.33% | -2,917.39% |
| Issuance of Common Stock | -84.34% | -65.14% | 6,804.96% | 615.47% | -44.76% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -86.81% | -69.38% | 6,848.03% | 623.05% | -45.23% |
| Foreign Exchange rate Adjustments | -2,900.00% | 450.43% | -165.19% | -10,850.00% | 140.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 3,863.80% | -139.19% | 369.41% | -24.16% | -95.52% |
